Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T21:51:23.758Z.
Calculation as of: 2026-10-06T21:51:23.758Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4cebeea1a9b4d788b134268ad244658713bcf5e38577c227b803d15950d20ec6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Market Cap
$5.82M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) | $5.82M | N/A |
| Lucyd, Inc (LUCY)vs › | $5.83M | N/A |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.89M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.73M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.92M | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $6.11M | N/A |
| Femasys Inc. (FEMY)vs › | $6.28M | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
